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Abstract
Background: Diabetes specific emotional problems interfere with the demanding daily
management of living with type 2 diabetes mellitus (T2DM). Possibly, offering direct feedback on
diabetes management may diminish the presence of diabetes specific emotional problems and might
enhance the patients' belief they are able to manage their illness. It is hypothesized that self-
monitoring of glucose in combination with an algorithm how and when to act will motivate T2DM
patients to become more active participants in their own care leading to a decrease in diabetes
related distress and an increased self-efficacy.
Methods and design: Six hundred patients with T2DM (45 ≤ 75 years) who receive care in a
structured diabetes care system, HbA1c ≥ 7.0%, and not using insulin will be recruited and
randomized into 3 groups; Self-monitoring of Blood Glucose (SMBG), Self-monitoring of Urine
Glucose (SMUG) and usual care (n = 200 per group). Participants are eligible if they have a known
disease duration of over 1 year and have used SMBG or SMUG less than 3 times in the previous
year. All 3 groups will receive standardized diabetes care. The intervention groups will receive
additional instructions on how to perform self-monitoring of glucose and how to interpret the
results. Main outcome measures are changes in diabetes specific emotional distress and self-
efficacy. Secondary outcome measures include difference in HbA1c, patient satisfaction,
occurrence of hypoglycaemia, physical activity, costs of direct and indirect healthcare and changes
in illness beliefs.
Discussion: The IN CONTROL-trial is designed to explore whether feedback from self-
monitoring of glucose in T2DM patients who do not require insulin can affect diabetes specific
emotional distress and increase self-efficacy. Based on the self-regulation model it is hypothesized
that glucose self-monitoring feedback changes illness perceptions, guiding the patient to reduce
emotional responses to experienced threats, and influences the patients ability to perform and
maintain self-management skills.
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Diabetes specific emotional problems can interfere with
the strict regime type 2 diabetes mellitus (T2DM)
demands. Emotional problems, such as not accepting dia-
betes, fear for hypoglycaemia and worrying about compli-
cations, might impact aspects of quality of life, for
example, increase diabetes related distress, which in turn
might affect self-care behaviours and glycaemic control
[1,2]. Diabetes self-management can protect against the
development of diabetes specific distress [3] and it can
have a positive effect on perceived self-efficacy [4]. Possi-
bly, common self-management factors such as guidance
in accepting diabetes, formulating clear and concrete
goals [3] as well as personal confidence and belief in the
ability to recognize, understand and act on symptoms
related to T2DM may be helpful in reducing levels of dis-
tress [5]. An example of a self-management method is glu-
cose self-monitoring. Based on collecting data of glucose
levels on different time-points, self-monitoring and its
feedback might help patients to a better understanding of
day to day variation in glucose levels. With the self-moni-
toring information, lifestyle adjustments can be made,
provided the patient is informed how to interpret the
results and what actions to take.
The hypothesis that self-monitoring of glucose empowers
the patient by its feedback is based on the principles of
Leventhal's self-regulation model [6,7]. This model pro-
poses that individuals construct schematic perceptions of
illness and health-threatening conditions according to
sources of information that are available to them. These
illness perceptions determine how patients respond when
confronted with their illness or related threats and are
mediators in the willingness and ability to take action.
Feedback on the illness condition allows adaption of ill-
ness perceptions, which lead to changes in self-efficacy
and illness specific distress.
Previous research
To date, research in self-monitoring of glucose has prima-
rily focused on reaching and maintaining glycaemic con-
trol. Therefore, up to now the evaluation of success or
failure of self-monitoring has been based upon its ability
to decrease HbA1c to normal values.
Self-monitoring of glucose has been proven successful in
regulating HbA1c in patients with type 1 diabetes [8] and
T2DM requiring insulin [9]. For T2DM patients not using
insulin this is still a matter of debate [10-12]. Meta-analy-
ses on self-monitoring of blood glucose (SMBG) in T2DM
not using insulin revealed small effects on HbA1c [13-15].
The improvements shown were clinically relevant and sta-
tistically significant. Nevertheless, in all reviews the meth-
odological quality of the studies included was questioned.
The recently well-designed DiGEM trial addressed most of
the methodological comments on the previous studies
and found no effects on glycaemic control in T2DM
patients not requiring insulin [16].
Before the widespread extent of SMBG, self-monitoring of
urine glucose (SMUG) was used to indicate episodes of
hyperglycaemia during the corresponding urine excretion
time. Even though urine glucose excretion is influenced
by renal threshold, SMUG can provide basic information
on glycaemic status. Furthermore, feedback derived from
SMUG can motivate T2DM patients to become actively
engaged in self-management of T2DM [17], irrespective of
the monitoring technique. Nevertheless, it is unknown if
SMUG provides enough feedback to influence illness per-
ceptions and subsequently diminish diabetes related dis-
tress.
Whether self-monitoring of glucose can help patients to
better understand their diabetes and to an increased self-
efficacy and less diabetes related distress is not known and
has not been investigated as a primary objective yet. Infor-
mation from qualitative research suggest that self-moni-
toring of glucose may have a negative impact regarding
aspects of quality of life and patient-satisfaction [18-20].
Possibly, insufficient knowledge in how and when to per-
form and interpret SMBG might lead to these results.
In this trial the effect of self-monitoring of glucose regard-
ing diabetes-specific distress and self-efficacy in combina-
tion with education in self-monitoring and an algorithm
what to do is evaluated.
IN CONTROL Objectives
The aim of the study is to assess the effects of SMBG and
SMUG in patients with type 2 diabetes who are not using
insulin compared to usual care. Primary outcome meas-
ures are changes in diabetes specific emotional distress
and self-efficacy. Secondary outcomes are changes in gly-
caemic control, patient treatment satisfaction, physical
activity, health status, status of depression, occurrence of
hypoglycaemia, cost-effectiveness and cost-utility. As part
of a process evaluation changes in illness perceptions, per-
ceived severity and social support are determined as well.
Methods
Design of the study
"IN CONTROL" entails a 3-armed randomized clinical
trial performed in the province of Noord-Holland, The
Netherlands. The Medical Ethical Committee of the VUmc
approved the study design, protocols, information letters
to the patients and informed consent form.
Setting
The participating diabetes care systems provide and man-
age regional diabetes care in addition to the care of gen-Page 2 of 8
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systems are based on the chronic care model [21-23] and
coordinate regional diabetes care using a centrally organ-
ized database which is available for all involved caregiv-
ers. Each patient is annually invited for a physical
examination and a visit with a diabetes nurse and a dieti-
cian for information, education and advise. This visit
includes assessment and discussion of glucose control and
the presence of complications. If necessary, follow-up vis-
its are scheduled. The results of the visits are sent to the
patients' general practitioner (GP) who is responsible for
the management of the patients.
Study population
In total 600 consenting participants will be recruited.
Patients are considered eligible if they are diagnosed with
T2DM and meet the following criteria:
❑ known disease duration of over 1 year
❑ recent HbA1c ≥ 7.0%
❑ treated with diet and/or oral hypoglycaemic agents
❑ do not require insulin at inclusion
❑ aged between 45 and 75 years
❑ used SMBG or SMUG less than 3 times in the previ-
ous year
Participants will be randomly assigned to one of the fol-
lowing 3 groups (figure 1):
❑ intervention group A, performing SMBG with spe-
cific SMBG education, in addition to usual diabetes
care provided by the regional diabetes care system.
❑ intervention group B, performing SMUG with spe-
cific SMUG education, in addition to usual diabetes
care provided by the regional diabetes care system.
❑ control group receiving usual diabetes care provided
by the regional diabetes care system.
Randomization
For intervention allocation a randomization list is drawn
up using a computerized randomization computer pro-
gram (Random Allocation Software version 1.0.0). As dif-
ferent effects may be expected of prescribed drug
treatments that are likely to cause hypoglycaemia, for
example sulfylureas or glinides (SU), randomization will
be pre-stratified by treatment (using SU or not (Non-SU)).
A research-manager, who is not involved in the patients
care, allocates the patient to one of the 3 groups by using
the randomization list. Intervention allocation will be
concealed for the principal investigator who is responsible
for the data analyses. Participants may withdraw from the
study at their own request and without providing reasons.
Date of withdrawal will be recorded and effort will be
made to contact participants lost to follow up. Only par-
ticipants withdrawn prior to randomization will be
replaced.
Intervention groups (SMBG & SMUG)
Following randomization participants allocated to one of
the intervention groups receive a training in SMBG or
SMUG delivered by trained research assistants and a flow-
chart with instructions when to perform and how to inter-
pret self-monitoring. After this training participants
should be able to perform SMBG or SMUG and interpret
the results, identify factors that can influence glucose level
and identify when additional tests are needed.
The acquired skills in self-monitoring are checked and if
necessary corrected in a control visit of maximal 30 min-
utes, 7 to 14 days after randomization. During this visit a
stepwise script outlining the self-monitoring skills needed
is used. All participants in the SMBG group are requested
to measure their blood glucose twice a week (one week-
day, one weekend day) at 6 different time points a day
(fasting, 1 1/2 – 2 hrs after breakfast, before lunch, 1 1/2
– 2 hrs after lunch, before diner, before bedtime) with a
glucose-meter (LifeScan OneTouch® Ultra®2). Participants
in the SMUG group are requested to test their urine twice
a week (one weekday, one weekend day) in the evening
after dinner (Urispec™ plus urine glucose in vitro reagent
test strips). Both groups will receive a diary in which they
have to record the obtained values for blood or urine glu-
cose. To avoid extra psychological burden we allow partic-
ipants to adjust self-monitoring to a frequency 'they feel
comfortable with' starting from 2 months after baseline
until the end of the study.
Measurements
Outcome measures are obtained at baseline, 4 and 12
months. These are collected by self-administered ques-
tionnaires, blood sampling and anthropometry. Diabetes
specific distress is assessed by the Problem Areas In Diabe-
tes scale (PAID) [24,25] and self-efficacy by the Confi-
dence In Diabetes Self-care questionnaire (CIDS) [26]
adjusted for T2DM. Patient treatment satisfaction is
assessed by the Diabetes Treatment Satisfaction Question-
naire (DTSQ) [27], physical activity is assessed by the
short International Physical Activity Questionnaire
(IPAQ-7) [28], health status and cost utility are assessed
with the Euroqol-5D [29-31]. Status of depression is
assessed at baseline and at 12 months using the Patient
Health Questionnaire-9 (PHQ-9) [32], Demographic var-
iables on age, gender, diabetes duration, marital statusPage 3 of 8
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Design of the RCTFigure 1
Design of the RCT.
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of a self-administered questionnaire. Glycaemic control is
measured by HbA1c-level. Furthermore, BMI and blood-
pressure are measured. Participants are asked to register
occurrence of hypoglycaemia in care-diaries. Costs of
direct health care and indirect non-healthcare will be
inventoried in cost-diaries and recorded in 3-monthly
intervals. Table 1 summarizes the measures and their tim-
ing.
Process evaluation and quality assurance
A process evaluation will be performed to evaluate our
theories of the processes underlying the effect of self-mon-
itoring. For this evaluation changes in mastery are
assessed by the subscales personal control and treatment
control of the Revised Illness Perception Questionnaire
(IPQ-R) [33] and changes in perceptions of diabetes and
social support by the subscales perceived severity and per-
ceived social support from a significant other of the Mul-
tidimensional Diabetes Questionnaire (MDQ) [34].
These measures are assessed at 5 time-points (baseline, 2
months, 4 months, 6 months and 12 months) (Table 1).
A script outlining the topics to be covered per visit is used
to support the nurses and research assistants in their tasks.
Before inclusion all research assistants attend a training in
self-monitoring (SMBG and SMUG) and before the start
of the intervention their self-monitoring skills are tested
in a pilot. During the inclusion period the research assist-
ants are audited. Directly after the training the research
assistants are asked about their opinions about their
acquired skills in self-monitoring and their capability to
train and instruct participants following protocol (5-point
Likert scale; 1 = fully disagree, 5 = fully agree). This will
also be done after the inclusion period. The participants of
the intervention groups are asked to give their opinion on
6 items regarding skills, importance and motivation for
self-monitoring at baseline and 2 months after baseline
(5-point Likert scale).
Sample size
The proposed trial is designed to detect a clinically rele-
vant change of self-monitoring of glucose on diabetes spe-
cific emotional distress and self-efficacy. No consensus
exists about minimal important differences (MID) of dia-
betes specific distress measured with the PAID and self-
efficacy measured with the CIDS. Therefore we set the
MID at half a standard deviation [35]. In diabetes patients
the standard deviation (SD) of PAID (scores transformed
to 0–100) was 20 points [25]. Using a bonferroni correc-
tion based on two primary hypotheses with α 0.025 and
β 0.15, a sample size of 86 per group is needed to find a
difference of 10 points (0.5 SD). Information on the SD
of the CIDS is not yet available for T2DM patients. For
type 1 diabetes patients the SD of CIDS (scores trans-
formed to 0–100) was 12 points [26]. To detect a decrease
of 6 points (0.5 SD), while correcting according to bonfer-
roni based on two primary hypotheses with α 0.025 and
β 0.15 a sample size of 86 per group is needed. Taking into
account different effects in different treatment groups (SU
or non-SU) pre-stratification by treatment will double the
sample size. Assuming a 15% drop-out rate, a total of 600
T2DM patients with HbA1c ≥ 7.0% are needed in the
study. In addition, with a total of 600 patients it is
Table 1: Study measures
Measures Baseline 2 months 3 months 4 months 6 months 9 months 12 months
Physiological
BMI X X X
Blood pressure X X X
HbA1c X X X
Questionnaires
PAID X X X
CIDS X X X X X
PHQ-9 X X
DTSQ X X X
Euroqol-5D X X X
IPAQ-7 X X X
Process evaluation
IPQ-R subscales X X X X X
MDQ subscales X X X X X
Costs
Cost of medication X
Cost diaries X X X XPage 5 of 8
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evant decrease of 0.5% in HbA1c.
Analyses
On the basis of an intention-to-treat analysis, differences
between the intervention groups and usual care group are
calculated with 95% confidence intervals. In addition per
protocol analyses will be performed. The subgroups SU
and non-SU will be analysed separately for all outcome
measures. In case there is no effect modification by treat-
ment the data of both subgroups will be pooled. If there
are any relevant differences in baseline measurements
between the 3 arms, we will adjust the outcomes for these
factors (i.e. age, gender, ethnicity, status of depression,
diabetes duration, marital status, level of education). Lin-
ear and logistic regression will be used to determine the
effect of the intervention on each of the outcome meas-
urements. The effect of the intervention will be estimated
for sub-groups defined by duration of diabetes, socio-eco-
nomic status, perceived social support and perceived
severity of diabetes, glycaemic control and self-monitor-
ing frequency in order to gain a better understanding as to
who benefits most from the intervention. Analyses of
moderators and mediators will be performed for the proc-
ess-evaluation.
Economic analyses
For the economic evaluation from both the societal and
the health insurer perspective all costs related to diabetes,
and diabetic complications are considered relevant. Costs
of the intervention (SMBG or SMUG, visits to the GP,
medical specialists, therapists, dieticians and hospitaliza-
tion) are considered direct healthcare costs. The costs of
i.e. absence from paid and unpaid work are considered
indirect healthcare costs. Differences in mean costs
between the groups will be presented with 95% confi-
dence intervals. An incremental cost-effectiveness ratio
(ICER) will be given both for PAID and CIDS by dividing
the incremental mean costs by the incremental mean
reduction in PAID or CIDS score. A cost utility ratio will
estimate the incremental costs per Quality Adjusted Life
Year gained for the study period. Cost-effectiveness planes
and acceptability curves will be presented and 95% confi-
dence intervals will be estimated for the ICERs.
Discussion
This article presents a detailed description of a RCT,
designed to explore the effectiveness of SMBG and SMUG
on diabetes specific emotional distress and self-efficacy in
non-insulin dependent T2DM patients. The proposed trial
is sufficiently powered and, to the best of our knowledge,
the first to allow for conclusions on the effect of self-mon-
itoring of glucose on both diabetes specific emotional dis-
tress and glycaemic control in a large sample. In addition,
due to a pre-stratification in oral treatments likely to cause
hypoglycaemia or not, a possible interaction with type of
treatment can be discovered. With the use of a theoretical
model as a base for our hypothesis the evaluation of proc-
esses theoretically underlying the (in)effectiveness of our
trial will be allowed as well. Therefore, this trial will make
an important contribution to the evidence of self-moni-
toring in non-insulin requiring patients with T2DM.
Franciosi et al. [36] reported that a self-monitoring fre-
quency of more than 1 measurement a day was related
with the development of diabetes related distress in
T2DM patients not using insulin. Unfortunately, master-
ing a new skill is coupled with practicing and thus a rela-
tively high frequency. By offering participants in the
intervention groups a training in self-monitoring, a con-
trol visit and a flowchart with instructions when to per-
form and how to interpret self-monitoring we believe that
a 2 months period should be sufficient to familiarize with
the self-monitoring skills considered necessary. In addi-
tion, development of diabetes-related distress caused by a
high monitoring frequency is targeted by giving the partic-
ipants the opportunity to independently adjust the pre-
scribed self-monitoring frequency to one 'they feel
comfortable with' starting two months after baseline.
As glycaemic control is an important issue in diabetes care
most research regarding self-monitoring has focused on
clinically relevant changes in HbA1c [16,37-40]. This trial
primarily focuses on the effect of self-monitoring on dia-
betes specific distress and is additionally sufficiently pow-
ered to detect a clinically relevant decrease of 0.5% in
HbA1c.
This trial will deliver important insights in the effects of
self-monitoring of glucose in T2DM patients not using
insulin on diabetes related distress and self-efficacy and
the role of possible barriers and facilitators underlying its
(in)effectiveness.
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